副鼻こう炎に対するセアプローゼＳの薬効評価　Ｉ　　Ｐｌａｃｅｂｏとの二重盲検比較試験成績

DOI Web Site

書誌事項

タイトル別名
  • Evaluation of SAP (Seaprose S) in the Treatment of Sinusitis (1st. Report)
  • フクビクウエン ニ タイスル セアプローゼ S ノ ヤッコウ ヒョウカ 1 P
  • Placebo との二重盲検比較試験成績

この論文をさがす

抄録

The efficacy of SAP was compared in a double blind study with that of a placebo in patients with chronic sinusitis. The daily dose of SAP was 45mg (3 tablets) and the duration of treatment was 4 weeks. The total number of patients evaluated was 125 in the SAP group and 130 in the placebo group.<br>The results were as follows:<br>1. The SAP group had a significantly better in global utility rating than the placebo group.<br>2. The global improvement rating of the SAP group was significantly better than that of placebo group.<br>3. The SAP group showed greater improvement than the placebo group in respect to postnasal drip and to the decrease in viscosity of nasal secretion.<br>4. X-rays of the sinuses showed definitely improvement of the right maxillary sinus in the SAP group.<br>5. Side-effects were noted in 5.6% of SAP group and in 4.6% of the placebo group, not a significant difference.<br>The results of this study suggest that SAP is a useful drug in the treatment of chronic sinusitis.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ